Major depressive disorder affects around 16 per cent of the world population at some point
in their lives. Despite the availability of numerous monoaminergic-based antidepressants, …

… Method development and quantitation WJ LOUGH and IW WAINER … 12 Food, organic
and pharmaceutical applications WJ LOUGH and IW WAINER … WJ LOUGH and IW WAINER …

… Pradhan B, Mitrev L, Moaddell R, Wainer IW. D-serine is a potential biomarker for clinical
response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and …

BACKGROUND: Ketamine has rapid antidepressant effects lasting as long as 1 week in
patients with major depressive disorder (MDD) and bipolar depression (BD). Ketamine is …

The effect of the (R,S)-ketamine metabolites (R,S)-norketamine, (R,S)-dehydronorketamine,
(2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine on the activity of α7 and …

Aims The present study was conducted to evaluate metabolism of the enantiomers of verapamil
and norverapamil using a broad range of cytochrome P450 isoforms and measure the …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • (R,S)‐ketamine is a phencyclidine
derivative that was initially developed as an anaesthetic agent and which is currently being …

… Wainer, Moaddel Bernier and Zarate have assigned their rights in the patent to the US
government, but will receive a percentage of any royalties that may be received by the government…

Purpose Prognosis is poor for Ewing sarcoma patients with metastasis at diagnosis. We
intensified a five-drug therapy (ifosfamide, etoposide alternated with vincristine, doxorubicin, …

Background: Subanesthetic doses of (R,S)-ketamine are used in the treatment of neuropathic
pain and depression. In the rat, the antidepressant effects of (R,S)-ketamine are associated …